All Photos(2)

Documents

L6545

Letrozole

Name: Letrozole
Brand: SIGMA

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

Synonym(s):

4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile

Sign Into View Organizational & Contract Pricing

All Photos(2)

About This Item

Empirical Formula (Hill Notation):

C₁₇H₁₁N₅

CAS Number:

112809-51-5

Molecular Weight:

285.30

MDL number:

MFCD00866241

UNSPSC Code:

51111800

PubChem Substance ID:

329817641

NACRES:

NA.77

product name

Letrozole, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >50 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3

InChI

1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

InChI key

HPJKCIUCZWXJDR-UHFFFAOYSA-N

Gene Information

human ... CYP19A1(1588)

Looking for similar products? Visit Product Comparison Guide

Application

Letrozole has been used:

in organoid growth assay to determine its inhibitory capacity(48)
to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
to determine its effects on tumor-induced hyperalgesia(50)
for hormonal manipulation in rats(51)
to study its effects on lipocalin-2 (Lcn2)(52)
to determine its effects on mechanical hyperalgesia and aromatase expression(53)

Biochem/physiol Actions

Letrozole acts as an adjuvant agent and is used to treat breast cancer.

Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

GHS08

Signal Word

Warning

Hazard Statements

H361fd,H373

Precautionary Statements

P202 - P260 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2 - STOT RE 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Drugs for Pregnant and Lactating Women E-Book (2009)

Organizational Effects of Estrogens and Androgens on Estrogen and Androgen Receptor Expression in Pituitary and Adrenal Glands in Adult Male and Female Rats.

Natalia Lagunas et al.

Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)

Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.

Bianca Posocco et al.

PloS one, 15(2), e0228822-e0228822 (2020-02-08)

A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Dennis C Sgroi et al.

Journal of the National Cancer Institute, 105(14), 1036-1042 (2013-07-03)

Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)-positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node-negative breast cancer patients. H/I was evaluated in MA.17 trial for prognostic performance

Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).

Rob Riemsma et al.

Current medical research and opinion, 28(8), 1263-1279 (2012-06-29)

Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen. For HR+, HER2+ MBC, combination of an AI with an anti-HER2 agent (lapatinib or trastuzumab) has shown clinical benefit. Six databases were

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service